NIQ Unveils New Brand Identity Reflecting Commitment to the Full View of Consumer Intelligence
1.3.2023 15:00:00 EET | Business Wire | Press release
NIQ, the global leader in consumer intelligence, has launched a new brand identity, reflecting the company’s industry-leading insights and measurement capabilities, revealing new pathways to growth for retailers and brands. The new branding aligns with a significant transformation across the organization and represents a commitment to delivering the most complete and clear understanding of consumers globally – the Full View.
NIQ’s Full View is powered by more—more data from more channels, sources, consumers, and regions. Understanding, measuring, and activating on complete data provides an unparalleled opportunity for clients to gain a competitive advantage, capitalize on opportunities, mitigate risks, and understand evolving consumer shopping behavior. With the clearest understanding of consumer behavior, delivered through an advanced platform with integrated analytics, businesses can make confident decisions that will drive growth.
“The new brand identity balances our legacy and our future as the leader in consumer intelligence,” says Tracey Massey, Chief Operating Officer, NIQ. “In 1923, our company created the concept of market share, and now, with our investments in omnichannel, NIQ’s identity signifies the new standard for understanding what consumers buy, why they make purchase decisions, and most importantly, how our clients can win.”
New elements of the brand identity include revamped company name, logo, colors, and purpose. Together, they signal the company’s evolution and signify leadership in omnichannel consumer intelligence.
- Name/Logo: NIQ, builds on the company’s legacy and reinvents itself for the future.
- Color palate: The diverse range of colors support NIQ’s advanced Connect platform and Discover data visualization platform, a robust and intuitive business intelligence tool that interacts with the most complete consumer data sets around the world.
- Brand purpose: “Show the world what people want,” focuses the company’s strategy and employee value proposition.
- Brand promise: “We deliver the Full View, the world’s most complete and clear understanding of consumer buying behavior that reveals new pathways to growth,” shows clients our uniquely ambitious point of view.
“Our new identity embodies the renewed sense of purpose, and energy across the company, that embraces change, innovation, and solves the industry's biggest challenges,” says Marta Cyhan-Bowles, Chief Communication Officer & Head of Marketing, North America. “This is a milestone year for NIQ, as the company accelerates our vision for the world to see us for who we truly are, a pathway to growth.”
NIQ’s new identity will be showcased at the annual Consumer 360® conference as the company breaks new passages towards purpose, defines new inroads for innovation, creates new bridges for collaboration, and maps new pathways to growth.
For more information about NIQ and to view the new brand identity, please visit www.niq.com.
About NIQ
NIQ, the world’s leading consumer intelligence company, reveals new pathways to growth for retailers and consumer goods manufacturers. With operations in more than 100 countries, NIQ delivers the most complete and clear understanding of consumer buying behavior through an advanced business intelligence platform with integrated predictive analytics. NIQ delivers the Full View.
NIQ was founded in 1923 and is an Advent International portfolio company. For more information, visit NIQ.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005477/en/
Contact information
Media
Gillian Mosher (gillian.mosher@nielseniq.com)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom